Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Modalités de mise à disposition du rapport financier annuel 2025
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Communiqué de mise à disposition du rapport financier annuel 2025
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Target Price at $51.40
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
CRCAM Toulouse 31 - Rapport financier annuel 2025
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Brokerages Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $47.00
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $48.33
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Fantôme Rapport Launches in English — A Romance, Horror, and Mystery Adventure Aboard a Ghostly Luxury Liner
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 6,567 Shares
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport stock plunges 18% on Wednesday: what went wrong after 200% rally
Rapport Announces Pricing of Public Offering of Common Stock
Rapport Announces Proposed Public Offering of Common Stock
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Analysts Can't Get Enough of These Little-Known Biopharma Stocks